Looking to buy FOX-04 for laboratory senescence research? FOX-04, short for FOXO4 D-Retro-Inverso, is a synthetic research peptide designed to interfere with the interaction between the FOXO4 transcription factor and the p53 tumour-suppressor protein.<\/p>\n
This protein interaction has been investigated for its role in supporting the survival of certain senescent cells. Senescent cells have permanently stopped dividing but may remain metabolically active and release signalling molecules associated with tissue ageing and inflammatory processes.<\/p>\n
In a landmark 2017 preclinical study led by researchers affiliated with Erasmus University Medical Center Rotterdam, FOXO4-DRI preferentially reduced the viability of senescent cells by disrupting FOXO4\u2013p53 binding. This promoted the relocation of active p53 and initiated apoptosis in the senescent cells studied. Control cells were less affected under the specific experimental conditions used.<\/p>\n
Peptides Divas supplies FOXO4-DRI in a 10 mg format as a stable lyophilised powder. Each batch is accompanied by batch-specific analytical documentation.<\/p>\n
Ten produkt jest przeznaczony wy\u0142\u0105cznie do cel\u00f3w bada\u0144 laboratoryjnych. Nie jest przeznaczony do u\u017cytku przez ludzi ani zwierz\u0119ta.<\/strong><\/p>\n FOXO4-DRI is studied as an experimental senolytic peptide. In preclinical cell models, it has been shown to compete with FOXO4 for p53 binding, promoting p53 relocation from the nucleus and activating apoptosis-associated pathways in certain senescent cells.<\/p>\n These findings are model-dependent and should not be interpreted as evidence that FOXO4-DRI targets every type of senescent cell.<\/p>\n FOXO4 is a transcription factor involved in cellular stress responses, homeostasis and cell-fate regulation. In the investigated senescent-cell models, FOXO4 helped retain p53 within the nucleus. FOXO4-DRI was designed to interfere with this interaction and release p53 from these nuclear complexes.<\/p>\n In mouse models, experimental FOXO4-DRI administration was associated with improvements in selected measures of tissue homeostasis, including markers related to kidney function, fur density and physical activity. These results were obtained in animals and cannot be directly extrapolated to humans.<\/p>\n FOXO4-DRI uses a D-retro-inverso design in which D-amino acids are arranged in reverse sequence order. This design is commonly investigated as a method of preserving functional side-chain orientation while increasing resistance to proteolytic degradation compared with corresponding conventional L-peptides.<\/p>\n The exact stability and performance of an individual batch depend on its composition, handling and experimental conditions.<\/p>\n Some senescent cells produce a collection of inflammatory cytokines, growth factors and proteases known as the senescence-associated secretory phenotype, or SASP.<\/p>\n By investigating the selective removal of senescent cells, researchers may study whether FOXO4-DRI influences SASP-related signalling and inflammatory processes in controlled experimental models. This remains a preclinical research field and is not an established clinical application.<\/p>\n Every FOXO4-DRI batch is supplied with a Certificate of Analysis. Depending on the available batch documentation, analytical testing may include:<\/p>\n Always consult the Certificate of Analysis for the exact specifications and analytical results of the supplied batch.<\/p>\n FOXO4-DRI 10 mg is supplied exclusively for controlled scientific and laboratory research. It is not a medicine, food supplement or cosmetic product and is not approved for human consumption, therapeutic applications, clinical use or veterinary use.<\/p>","protected":false},"excerpt":{"rendered":" Looking to buy FOXO4-DRI for laboratory senescence research? FOXO4-DRI, short for FOXO4 D-Retro-Inverso, is a synthetic research peptide designed to interfere with the interaction between the FOXO4 transcription factor and the p53 tumour-suppressor protein.<\/p>\n This protein interaction has been investigated for its role in supporting the survival of certain senescent cells. Senescent cells have permanently stopped dividing but may remain metabolically active and release signalling molecules associated with tissue ageing and inflammatory processes.<\/p>\n In a landmark 2017 preclinical study led by researchers affiliated with Erasmus University Medical Center Rotterdam, FOXO4-DRI preferentially reduced the viability of senescent cells by disrupting FOXO4\u2013p53 binding. This promoted the relocation of active p53 and initiated apoptosis in the senescent cells studied. Control cells were less affected under the specific experimental conditions used.<\/p>\n Peptides Divas supplies FOXO4-DRI in a 10 mg format as a stable lyophilised powder. Each batch is accompanied by batch-specific analytical documentation.<\/p>\n Ten produkt jest przeznaczony wy\u0142\u0105cznie do cel\u00f3w bada\u0144 laboratoryjnych. Nie jest przeznaczony do u\u017cytku przez ludzi ani zwierz\u0119ta.<\/strong><\/p>","protected":false},"featured_media":741,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"nf_dc_page":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"product_brand":[],"product_cat":[34],"product_tag":[46],"class_list":["post-740","product","type-product","status-publish","has-post-thumbnail","product_cat-recovery-repair","product_tag-10-mg","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\nFOXO4-DRI Product Specifications<\/h2>\n
\n\n
\n \nSpecyfikacja<\/th>\n Bli\u017csze dane<\/th>\n<\/tr>\n<\/thead>\n \n Nazwa produktu<\/td>\n FOXO4-DRI<\/td>\n<\/tr>\n \n Pe\u0142ne imi\u0119 i nazwisko<\/td>\n FOXO4 D-Retro-Inverso peptide<\/td>\n<\/tr>\n \n Kwota<\/td>\n 10 mg na fiolk\u0119<\/td>\n<\/tr>\n \n Kategoria bada\u0144<\/td>\n Cellular senescence and senolytic research<\/td>\n<\/tr>\n \n Investigated mechanism<\/td>\n Disruption of the FOXO4\u2013p53 protein interaction<\/td>\n<\/tr>\n \n Czysto\u015b\u0107<\/td>\n \u226599.5% by HPLC<\/td>\n<\/tr>\n \n Formularz<\/td>\n Liofilizowany proszek<\/td>\n<\/tr>\n \n Peptide design<\/td>\n D-retro-inverso structure<\/td>\n<\/tr>\n \n Sk\u0142adowanie<\/td>\n Przechowywa\u0107 w temperaturze \u221220\u00b0C, chroni\u0107 od \u015bwiat\u0142a i wilgoci.<\/td>\n<\/tr>\n \n Dokumentacja<\/td>\n Certyfikat analizy dla konkretnej partii<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Scientific Research Relevance<\/h2>\n
Senescent-Cell Research<\/h3>\n
FOXO4\u2013p53 Interaction<\/h3>\n
Ageing-Biology Research<\/h3>\n
D-Retro-Inverso Peptide Design<\/h3>\n
SASP and Inflammation Research<\/h3>\n
Quality Assurance<\/h2>\n
\n
Tylko do cel\u00f3w badawczych<\/h2>\n
FOXO4-DRI 10 mg \u2013 Senolytic Research Peptide<\/h1>\n